Aarti Drugs Limited announced on January 29, 2026, that CRISIL Limited has reaffirmed the company's credit ratings. The long-term rating for bank facilities totaling ₹1,768 Crores has been reaffirmed as CRISIL AA-/Stable. Additionally, the short-term rating has been reaffirmed as CRISIL A1+. This reaffirmation pertains to the total bank loan facilities rated at ₹1,768 Crores. The company has informed the BSE and NSE about this update in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
